The reproductive "master switch" — with real modern clinical science and three great backstories. This is one of the register's stronger entries: a genuine upstream controller of human reproduction, backed by actual randomized trials (Imperial College London), yet still research-only. Three threads
Kisspeptin-10 is the minimal active fragment of kisspeptin — the hypothalamic peptide that sits at the top of the reproductive hormone axis and acts as its master switch. It works upstream: activating KISS1R on GnRH neurons, which drives pulsatile GnRH → LH/FSH → testosterone/estradiol. Its story is unusually rich: the gene was named after Hershey's Kisses chocolate, was discovered in cancer research (as the metastasis suppressor "metastin") before its reproductive role was known, and proved essential when people lacking it were found not to undergo puberty. Crucially — and unlike most compounds here — kisspeptin has real, current clinical science behind it: Imperial College London teams have run trials in hypogonadism, IVF triggering, hypothalamic amenorrhea, and hypoactive sexual desire disorder, where randomized placebo-controlled studies showed it modulates the brain's arousal/"attraction" circuits and reduces sexual aversion. The honest caveats: it's still research-only (not approved), its strongest data are in specific clinical settings (not the bodybuilding "testosterone restart" use it's often sold for), and it has a very short half-life. Bottom line: a genuinely important hormone with real translational momentum — promising and well-studied, but not yet an approved therapy.
research use only; not approved by FDA or EMA for any therapeutic use. But — unlike most gray-market peptides — it has an active, legitimate clinical-trial pipeline (Phase 1/2), so its "unproven" status is "not yet approved, actively being developed," not "fringe."
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (active clinical pipeline — watch for Phase 2/3 progress in IVF triggering and HSDD; approval would move several grades).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.